The EPHMRA/Intellus ATC Classification Committee is embarking on a pivotal reorganization of the L-class within the Anatomical Classification (ATC) system. This significant change aims to better distinguish antineoplastic (oncology) therapies from immunological products, creating a clearer and more adaptable framework for emerging innovations in both therapeutic areas.
This webinar covers:
1. Address current challenges
2. Outline the proposed changes and implementation timeline
3. Encourage industry feedback and address questions
Download slides here